Shulei Zhu
Innovation Center for AI and Drug Discovery, East China Normal University
slzhu@chem.ecnu.edu.cn
Brief Biography:
Dr. Shulei Zhu currently serves as an Associate Professor at the Innovation Center for AI and Drug Discovery, East China Normal University. He received his bachelor degree in Pharmacy at China Pharmaceutical University in 2015, and received his Ph.D. degree in Organic Chemistry at East China Normal University in 2020, respectively. He worked as a Postdoc in Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development at East China Normal University from July 2020 to September 2023. His research was supported by the Youth Science Fund from the National Natural Science Foundation of China (NSFC) and industry collaborative research projects. Presently, he has published 16 SCI papers on Asian J. Pharm. Sci., J. Med. Chem., Eur. J. Med. Chem. etc, and applied for 10 patents. He has participated and developed the “Novel Antibody-Drug Conjugate Platform” with multiple candidate drugs being transferred and 2 drugs being in clinical trials.
Education Background
2011.09-2015.06, B.S., Pharmacy, China Pharmaceutical University
2015.09-2020.07, Ph.D., Organic Chemistry, East China Normal University
Work Experience
2020.07-2023.09, East China Normal University, Postdoc
2023.10-, East China Normal University, Associate Professor
Research Interests:
1. Novel antibody drug conjugates
2. Drugs related to cellular senescence
3. Novel drug delivery system
Selected Publications:
1. Zhu, S. L.; Li, Y. L.; Huang, Y. S.; Zhang, M. M.; Gu, X. F.; He, Y.; Liu, H. C.; Ma, M. L.*; Lu, W*. Optimized HSP90 mediated fluorescent probes for cancer-specific bioimaging. Journal of Materials Chemistry B, 2020, 8, 1878-1896.
2. Zhu, S. L.; Shen, Q. Q.; Gao, Y. L.; Wang, L.; Fang, Y. F.*; Chen, Y.; Lu, W*. Design, synthesis and biological evaluation of HSP90 inhibitor-SN38 conjugates for targeted drug accumulation. Journal of Medicinal Chemistry, 2020, 63, 5421-5441.
3. Zhu, S. L.; Yu, X. M.; He, Y.; Ma, M. L.*; Lu, W*. Synthesis and fluorescent studies of a low molecular weight rotor for living cancer cell imaging. Dyes and Pigments, 2020, 178, 108353.
4. Zhen, Z.#; Zhu, S. L.#; Jin, J. Y.; Wang, L.*; Lu, W*. A water-soluble probe with p-hydrobenzyl quaternary ammonium linker for selective imaging in senescent cells. Analytica Chimica Acta, 2020, 1133, 99-108.
5. Zhu, S. L.; Lu, Y. X.; Jin, J. Y.*; Yu, J. H.; Lu, W*. An HSP90 inhibitor based fluorescent probe for selective tumor targeting. Dyes and Pigments, 2021, 196, 109783.
6. Zhu, S. L.; Liu, J. Y.; Xiao, D. H.; Wang, P. P.; Ma, J. K.; Hu, X. B.; Fu, J. F.; Zhou, Y. B.*; Li, J.*; Lu, W*. Design, synthesis, and biological evaluation of Wee1 kinase degraders. European Journal of Medicinal Chemistry, 2022, 243, 114786.
7. Ding, M. Y.; Shao, Y. Y.; Sun, D. W.; Meng, S. R.; Zang, Y.; Zhou, Y. B.; Li, J.; Lu, W.; Zhu, S. L.* Design, synthesis, and biological evaluation of BRD4 degraders. Bioorganic & Medicinal Chemistry, 2022, 78, 117134.
8. Sun, L.; Zhang, J. F.; Zhou, J. E.; Wang, J.; Wang, Z. H.; Luo, Y. Y.; Zhu, S. L.*; Yang, F.; Tang, J.; Lu, W.; Wang, Y. T.; Yu, L.; Yan, Z. Q*. Monitoring the in vivo siRNA release from lipid nanoparticles based on the fluorescence resonance energy transfer principle. Asian Journal of Pharmaceutical Sciences, 2023, 18, 100769.
9. Cao, Y. T.; Shen, Q. Q.; Ding, M. Y.; Lu, W.; Zhu, S. L.* Development of HSP90 inhibitors-SN38 conjugates for cancer treatment. Bioorganic Chemistry, 2023, 137, 106582.
10. Ding, M. Y.; Shen, Q. Q.; Lu, W*; Zhu, S. L.*. Design, synthesis and biological evaluation of 4-(1H-1,2,3-triazol-1-yl)benzamides as HSP90 inhibitors. Molecular Diversity, 2023, 27, 239-248.